Skip to main content
. 2022 Mar 17;13:795972. doi: 10.3389/fimmu.2022.795972

Figure 3.

Figure 3

Radiologic, colonoscopic and pathological response to nIT with Tislelizumab in two patients with MSI-H/dMMR LARC (cCR). (A, D) Imaging: Pretreatment (R) VS After 6 cycles of nIT (L); (B, E) Colonoscopy: Pretreatment (R) VS After 6 cycles of nIT with (L); (C, F) Pathology: Pretreatment tumor biospy (R) VS Re-biospy after 6 cycles of nIT (L).